CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors

Purpose

The purpose of this study is to determine the safety and tolerability of monotherapy CR-001 and identify the maximum tolerated dose (MTD), and/or optimal biologic dose and Recommended Phase 2 Dose(s) (RP2D) in participants with locally advanced or metastatic solid tumors.

Condition

  • Locally Advanced / Metastatic Solid Tumors

Eligibility

Eligible Ages
Over 18 Years
Eligible Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Life expectancy ≥ 3 months - Eastern Cooperative Oncology Group (ECOG) performance status score of 0 - 1 - Adequate organ function and hematologic reserve based on laboratory parameters - Have measurable disease defined by RECIST v1.1 - For Backfill and Dose Optimization: Willingness to provide recent archival tumor tissue sample or willingness to undergo biopsy - Tumor Indication specific inclusion criteria: - For dose escalation or backfill: progressing from, intolerant to, or ineligible for (due to unavailability or contraindication) local standard of care therapies and have one of the following locally advanced or metastatic tumor types: - Hepatocellular carcinoma - Biliary tract cancer - Endometrial carcinoma - Cervical cancer - Ovarian cancer - Gastric or gastroesophageal cancer - Colorectal cancer - Non-small cell lung cancer

Exclusion Criteria

  • Has malignancies other than disease under study within the past 3 years - Has conditions requiring treatment with clinically significant or increasing doses of systemic steroid therapy - Has not adequately recovered from recent major surgery - Has ongoing clinically significant toxicity related to prior therapy - Has active central nervous system (CNS) metastases - Has active autoimmune disease requiring systemic therapy in the past 2 years (replacement therapy is permitted) - Has a history of serious Grade ≥ 3 immune-related adverse event (irAE) - Has a history of noninfectious pneumonitis/interstitial lung disease - Has an active severe infection - Has received a live or attenuated vaccine within 30 days of the first dose - Has undergone prior allogeneic stem cell or solid organ transplantation - Has protocol-specified events related to gastrointestinal perforation, surgery, wound healing complications, and bleeding - Has clinically significant cardiovascular disease NOTE: Other protocol defined Inclusion and Exclusion criteria may apply.

Study Design

Phase
Phase 1/Phase 2
Study Type
Interventional
Allocation
Non-Randomized
Intervention Model
Sequential Assignment
Primary Purpose
Treatment
Masking
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
CR-001 Dose escalation 		Escalating dose levels of CR-001 to define the maximum tolerated dose of CR-001 in participants with locally advanced or metastatic solid tumors who are refractory to or unable to tolerate standard of care treatment, or for whom standard of care treatment is unavailable
  • Drug: CR-001
    Intravenous Infusion
Experimental
CR-001 Backfill 		Escalating dose levels of CR-001 Indication-specific cohort populations will be tested
  • Drug: CR-001
    Intravenous Infusion
Experimental
CR-001 Dose Optimization Cohort X 		monotherapy dose level (DL)-X Indication-specific cohort populations will be tested
  • Drug: CR-001
    Intravenous Infusion
Experimental
CR-001 Dose Optimization Cohort Y 		monotherapy DL-Y Indication-specific cohort populations will be tested
  • Drug: CR-001
    Intravenous Infusion

Recruiting Locations

Clinical Study Site
Denver 5419384, Colorado 5417618 80218

Clinical Study Site
Orlando 4167147, Florida 4155751 32827

Clinical Study Site
Sarasota 4172131, Florida 4155751 34236

Clinical Study Site
Nashville 4644585, Tennessee 4662168 37203

Clinical Study Site
Dallas 4684888, Texas 4736286 75230

More Details

Status
Recruiting
Sponsor
Crescent Biopharma, Inc.

Study Contact

Crescent Clinical Trials
617-430-5595
clinicaltrials@crescentbiopharma.com

Detailed Description

The study will initially comprise 3 parts: dose escalation, backfill, and dose optimization cohorts. The study will follow a stepwise approach, beginning with a typical dose escalation in participants with selected indications of advanced solid tumors. Additional participants will enroll in the backfill part at select dose levels that have been previously cleared for safety by the safety review committee. In dose optimization, participants will be randomized to one of two CR-001 dose levels. All participants will undergo a screening period, a treatment period of up to 2 years, a safety follow-up period, and long-term efficacy and survival follow-up. During the treatment period, participants will undergo clinical and safety assessments including disease assessment scans and blood laboratory safety, pharmacokinetic, and pharmacodynamic assessments. After treatment ends, disease scans will continue until disease progression, and long-term follow-up visits will be conducted by telephone every 3 months.